New pharmacologic approaches for the perioperative treatment of ischemic cardiogenic shock

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 19, Issue 1, 2005, Pages 97-108

  Lehmann, Andreas ^a   Boldt, Joachim ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Cardiogenic shock; Heart surgery; L NAME; Levosimendan

Indexed keywords

ADRENALIN; AMRINONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN NATRIURETIC PEPTIDE; CATECHOLAMINE; DOBUTAMINE; DOPAMINE; DOPEXAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; ENOXIMONE; GLYCERYL TRINITRATE; HALOTHANE; INOTROPIC AGENT; LEVOSIMENDAN; MILRINONE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NESIRITIDE; NEUROHORMONE; NICORANDIL; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; STREPTOKINASE; TEZOSENTAN; TISSUE PLASMINOGEN ACTIVATOR; TOBORINONE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AORTA BALLOON; ARTERY OCCLUSION; CALCIUM BLOOD LEVEL; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUNTERPULSATION; DRUG EFFECT; DRUG MECHANISM; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FIBRILLATION; HEMODYNAMICS; HUMAN; HYPERCALCEMIA; HYPERMETABOLISM; METABOLISM; OXYGEN CONSUMPTION; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TACHYPHYLAXIS; THROMBOCYTOPENIA;

EID: 13844250575     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2004.11.020     Document Type: Review

References (124)

1. J.S. Hochman Cardiogenic shock complicating acute myocardial infarction Expanding the paradigm Circulation 107 2003 2998 3002
2. J.S. Hochman, L.A. Sleeper, J.G. Webb Early revascularazation in acute myocardial infarction complicated by cardiogenic shock N Engl J Med 341 1999 625 634
3. R.J. Goldberg, N.A. Samad, J. Yarzebski Temporal trends in cardiogenic shock complicating acute myocardial infarction N Engl J Med 340 1999 1162 1168
4. E. Verna, S. Repetto, M. Boscarini Emergency coronary angioplasty in patients with severe left ventricular dysfunction or cardiogenic shock after acute myocardial infarction Eur Heart J 10 1989 958 966
5. A.R. Moosvi, F. Khaja, L. Villanueva Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction J Am Coll Cardiol 19 1992 907 914
6. H. Yamamoto, Y. Yahashi, Y. Oka Efficacy of percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction complicated by cardiogenic shock Jpn Circ J 56 1992 815 882
7. M.D. Hibbard, D.R. Holmes Jr, K.R. Bailey Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock J Am Coll Cardiol 19 1992 639 646
8. D. Antoniucci, R. Valenti, G.M. Santoro Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction In-hospital and long-term survival J Am Coll Cardiol 31 1998 294 300
9. D. Himbert, J.M. Juliard, P.G. Steg Limits of reperfusion therapy for immediate cardiogenic shock complicating acute myocardial infarction Am J Cardiol 74 1994 492 494
10. J.S. Hochman, J. Boland, L.A. Sleeper Current spectrum of cardiogenic shock and effect of early revascularization on mortality Results of an international registry Circulation 91 1995 873 881
11. P. Urban, J.C. Stauffer, D. Bleed A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction the (Swiss) multicenter trial of angioplasty for shock--(S)MASH Eur Heart J 20 1999 1030 1038
12. P. Sergeant, B. Meyns, P. Wouters Long-term outcome after coronary artery bypass grafting in cardiogenic shock or cardiopulmonary resuscitation J Thorac Cardiovasc Surg 126 2003 1279 1286
13. T. Killip, J.T. Kimball Treatment of myocardial infarction in a coronary unit A two year experience with 250 patients Am J Cardiol 20 1967 457 464
14. J. Ducas, E.D. Grech Percutaneous coronary intervention cardiogenic shock BMJ 326 2003 1450 1452
15. H.A. Adams, G. Baumann, A. Gansslen Definition of shock types Anaesthesiol Intensivmed Notfallmed Schmerzther 36 suppl 2 2001 S140 S143
16. D.R. Holmes Cardiogenic Shock A lethal complication of acute myocardial infarction Rev Cardiovasc Med 4 2003 131 135
17. P.B. Berger, R.H. Tuttle, D.R. Holmes One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularazation Results from the GUSTO-I trial Circulation 99 1999 873 878
18. J.S. Hochman, L.A. Sleeper, H.D. White One-year survival following early revascularazation for cardiogenic shock JAMA 285 2001 190 192
19. The TRACE Study Group The TRAndoapril Cardiac Evaluation (TRACE) study Rationale, design, and baseline characteristics of the screened population Am J Cardiol 73 1994 44C 50C
20. J.S. Hochman, C.E. Buller, L.A. Sleeper Cardiogenic shock complicating acute myocardial infarction--Etiologies, management and outcome A report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36 suppl A 2000 1063 1070
21. D.R. Alonso, S. Scheidt, M. Post Pathophysiology of cardiogenic shock Quantification of myocardial necrosis, clinical, pathologic, and electrocardiographic correlations Circulation 48 1973 588 596
22. Y. Tsukahara, T. Morisaki, Y. Horita Expression of inducible nitric oxide synthase in circulating neutrophils of the systemic inflammatory response syndrome and septic patients World J Surg 22 1998 771 777
23. H. Drexler Nitric oxide synthase in the failing heart A double-edged sword? Circulation 99 1999 2972 2975
24. D.A. Wink, I. Hanbauer, M.C. Krishna Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species Proc Natl Acad Sci U S A 90 1993 9813 9817
25. C. Heymes, M. Vanderheylen, J.G. Bronzwaer Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy Circulation 99 1999 3009 3016
26. M. Flesch, H. Kilter, B. Cremers Acute effects of nitric oxide and cyclic GMP on human myocardial contractility J Pharmacol Exp Ther 28 1997 1340 1349
27. G. Cotter, E. Kaluski, A. Blatt L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock Circulation 101 2000 1358 1361
28. C. Depré, J.L. Vanoverschelde, J.F. Goudemant Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart Circulation 92 1995 1911 1918
29. R. Schulz, R. Wambolt Inhibition of nitric oxide synthesis protects the isolated working rabbit heart from ischemia-reperfusion injury Cardiovasc Res 30 1995 432 439
30. F. Brunner, P. Andrew, G. Woelkart Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase Circulation 104 2001 3097 3102
31. J.R. Holmes, E.R. Bates, N.S. Kleinman Contemporary reperfusion therapy for cardiogenic shock The GUSTO-I trial experience. The GUSTO-I Investigators J Am Coll Cardiol 26 1995 668 674
32. J.G. Webb, A.M. Lowe, T.A. Sanborn Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. The SHOCK investigators J Am Coll Cardiol 42 2003 1380 1386
33. E.M. Antman, D.T. Anbe, P.W. Amstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) Circulation 110 2004 588 636
34. G.W. Stone, E.M. Ohman, M.F. Miller Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction the benchmark registry J Am Coll Cardiol 41 2003 1940 1945
35. J.J. Ferguson, M. Cohen, R.J. Freedman The current practice of intra-aortic balloon counterpulsation Results from the Benchmark registry J Am Coll Cardiol 38 2001 1456 1462
36. E.M. Ohman, J.S. Hochman Aortic counterpulsation in acute myocardial infarction Physiologically important but does the patient benefit? A Heart J 141 2001 889 892
37. T.A. Sanborn, L.A. Sleeper, E.R. Bates Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction A report from the SHOCK Trial registry J Am Coll Cardiol 36 2000 1123 1129
38. H.V. Barron, N.R. Every, L.S. Parsons The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction data from the National Registry of Myocardial Infarction 2 Am Heart J 141 2001 933 939
39. W. Schutz, T. Anhaupl, A. Gauss Principles of catecholamine therapy. 1. Characterization of clinically relevant sympathomimetics Anaesthesiol Intensivmed Notfallmed Schmerzther 35 2000 67 81
40. A. Gauss, T. Anhaupl, W. Schutz Principles of catecholamine therapy. 2. A guide to clinical use Anaesthesiol Intensivmed Notfallmed Schmerzther 35 2000 131 136
41. C. Holubarsch New inotropic concepts Rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors Cardiology 88 suppl 2 1997 12 20
42. H. Haikala, P. Pollesello Calcium sensitivity enhancers Drugs 3 2000 1199 1205
43. K. Singh, L. Xiao, A. Remondino Adrenergic regulation of cardiac myocyte apoptosis J Cell Physiol 189 2001 257 265
44. M.R. Bristow, R.A. Hershberger, J.D. Port β-adrenergic pathways in nonfailing and failing human ventricular myocardium Circulation 82 suppl I 1990 I12 I25
45. R.M. Smiley, M.M. Kwatra, D.A. Schwinn New developments in cardiovascular adrenergic receptor pharmacology Molecular mechanisms and clinical relevance J Cardiothorac Vasc Anesth 12 1998 80 95
46. D.A. Schwinn Adrenorecptors as models for G protein-coupled receptors Structure, function and regulation Br J Anaesth 71 1993 77 85
47. J.V. Booth, K.P. Landolfo, L.C. Chesnut Acute depression of myocardial β-adrenergic receptors signaling during cardiopulmonary bypass--Impairment of the adenylyl cyclase moiety Anesthesiology 89 1998 602 611
48. M.R. Bristow, S.F. Shakar, J.V. Linseman Inotropes and beta-blockers Is there a need for new guidelines? J Card Fail 7 suppl 1 2001 8 12
49. J.N. Cohn Drug therapy The management of chronic heart failure N Engl J Med 335 1996 490 498
50. W.J. Remme, K. Swedberg Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology Guidelines for the diagnosis and treatment of chronic heart failure Eur Heart J 22 2001 1527 1560
51. S.A. Hunt, D.W. Baker, M.H. Chin ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult Executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure) Circulation 104 2001 2996 3007
52. ++-sensitizers for the treatment of heart failure Curr Opin Crit Care 9 2003 337 344
53. E.F. Du Toit, C.A. Muller, J. McCarthy Levosimendan effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart J Pharmacol Exp Ther 290 1999 505 514
54. W.J. Remme Inodilator therapy for heart failure. Early, late, or not at all? Circulation 87 suppl 1993 IV97 IV107
55. M. Packer, J.R. Carver, R.J. Rodeheffer Effect of oral milrinone on mortality in severe chronic heart failure the PROMISE Study Research Group N Engl J Med 325 1991 1468 1475
56. S. Thackray, J. Easthaugh, N. Freemantle The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure--A meta-regression analysis Eur J Heart Fail 4 2002 515 529
57. M. Goenen, O. Pedemonte, P. Baele Amrinone in the management of low cardiac output after open heart surgery Am J Cardiol 56 1985 33B 38B
58. S. Iversen, E. Mayer, U. Hake Efficacy of phosphodiesterase inhibitor enoximone in management of postcardiotomy cardiogenic shock Scand J Thorac Cardiovasc Surg 26 1992 143 149
59. J.L. Vincent, M. Leon, J. Berre Addition of phosphodiesterase inhibitors to adrenergic agents in acutely ill patients Int J Cardiol 28 suppl 1 1990 S7 S11
60. J.L. Vincent, E. Carlier, J. Berre Administration of enoximone in cardiogenic shock Am J Cardiol 62 1988 419 423
61. K. Kochi, S. Kyo, Y. Yokote The effect of milrinone for the shock patients after cardiac surgery Kyobu Geka 52 1999 239 242
62. J.B. Young New therapeutic choices in the management of acute congestive heart failure Rev Cardiovasc Med 2 suppl 2 2001 S19 S24
63. G.A. MacGowan Clinical overview of the novel inotropic agent toborinone Expert Opin Investig Drugs 9 2000 1109 1117
64. L.M. Semeniuk, I. Belenkie, J.V. Tyberg Acute effects of toborinone on vascular capacitance and conductance in experimental heart failure Circulation 98 1998 58 63
65. M.D. Feldman, P.H. Pak, C.C. Wu Acute cardiovascular effects of OPC-18790 in patients with congestive heart failure. Time- and dose-dependent analysis based on pressure-volume relations Circulation 93 1996 474 483
66. H. Kanda, M. Yokota, H. Ishihara A novel inotropic vasodilator, OPC-18790, reduces myocardial oxygen consumption and improves mechanical efficiency with congestive heart failure Am J Heart 132 1996 361 368
67. M. Ishikawa, T. Mori, S. Itoh Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischemic canine heart A 31P-MRS study Cardiovasc Res 30 1995 299 306
68. T. Hirata, T. Akamatsu, N. Horinokuchi Study on the effectiveness of toborinone (OPC-18790) in the treatment of heart failure in patients following cardiac surgery Arzneimittelforschung 49 1999 499 503
69. Z. Wu, T. Awaji, H. Abe Effects of OPC-18790, a new positive inotropic agent, on canine ventricular arrhythmias Jpn J Pharmacol 63 1993 399 404
70. J.C. Rüegg Towards a molecular understanding of contractility Cardioscience 1 1990 163 168
71. J. Levijoki, P. Pollesello, J. Kaivola Further evidence for the cardiac troponin C-mediated calcium sensitization by levosimendan Structure-response and binding analysis with analogs of levosimendan J Mol Cell Cardiol 32 2000 479 491
72. T. Sorsa, S. Heikkinen, M.B. Abott Binding of levosimendan, a calcium sensitizer, to cardiac troponin C J Biol Chem 276 2001 9337 9343
73. P. Kaheinen, P. Pollesello, J. Levijoki Effects of levosimendan and milrinone on oxygen consumption in isolated guinea pig heart J Cardiovasc Pharmacol 43 2004 555 561
74. H. Ukkonen, M. Saraste, J. Akkila Myocardial efficiency during levosimendan infusion in congestive heart failure Clin Pharmacol Ther 68 2000 522 531
75. I. Lepran, J.G. Papp Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in conscious rats Eur J Pharmacol 464 2003 171 176
76. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart Circ Res 77 1995 107 113
77. H. Haikala, P. Kaheinen, J. Levijoki The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan Cardiovasc Res 34 1997 536 546
78. P.M. Janssen, N. Datz, O. Zeitz Levosimendan improves diastolic and systolic function in failing human myocardium Eur J Pharmacol 404 2000 191 199
79. P. Kaheinen, P. Pollesello, J. Levijoki Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels J Cardiovasc Pharmacol 37 2001 367 374
80. + channel in rat ventricular cells J Pharmacol Exp Ther 283 1997 375 383
81. D.M. Kopustinskiene, P. Pollesello, N.E. Saris Levosimendan is a mitochondrial K(ATP) channel opener Eur J Pharmacol 428 2001 311 314
82. J. Pataricza, J. Hohn, A. Petri Comparison of the vasorelaxing effect of cromkalin and the new inodilator, levosimendan, in human isolated portal vein J Pharm Pharmacol 52 2000 213 217
83. J.R. Kersten, M.W. Montgomery, P.S. Pagel Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels Anesth Analg 90 2000 5 11
84. M. Loubani, M. Galinanes Pharmacological and ischemic preconditioning of the human myocardium MitoKATP channels are upstream and p38MAPK is downstream of PKC BMC Physiol 2 2002 10
85. L.P. Perrault, P. Menasche Preconditioning can nature's shield be raised against surgical ischemic-reperfusion injury? Ann Thorac Surg 68 1999 1988 1994
86. D.J. Patel, H.J. Purcell, K.M. Fox Cardioprotection by opening of the K(ATP) channels in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization Eur Heart J 20 1999 51 57
87. S. Sonntag, S. Sundberg, L.A. Lehtonen The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia J Am Coll Cardiol 43 2004 2177 2182
88. F. Follath, J.G. Cleland, H. Just Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO-study) A randomised double-blind trial Lancet 360 2002 196 202
89. V.S. Moiseyev, P. Poder, N. Andrejevs Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN) Eur Heart J 23 2002 1422 1432
90. G. Delle Karth, A. Buberl, A. Geppert Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines Acta Anaesthesiol Scand 47 2003 1251 1256
91. A. Lehmann, J. Lang, J. Boldt Levosimendan in patients with cardiogenic shock undergoing surgical revascularization A case series Med Sci Monit 10 2004 MT89 MT93
92. G. Torre-Amione, J.B. Young, J.B. Durand Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure Circulation 103 2001 973 980
93. T. Sakurai, M. Yanagisawa, T. Masaki Molecular characterization of endothelin receptors Trends Pharmacol Sci 13 1992 103 108
94. E. Ohlstein, S. Douglas Endothelin-1 modulates vascular smooth muscle structure and vasomotion Implications in cardiovascular pathology Drug Dev Res 29 1993 108 128
95. R. Takayanagi, K. Kitazumi, C. Takasaki Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation FEBS Lett 282 1991 103 106
96. S.S.D. Ry, M.G. Andreassi, A. Clerico Endothelin-1, endothelin-1 receptors and cardiac natriuretic peptides in failing human heart Life Sci 68 2001 2715 2730
97. G.G. Serneri, I. Cecioni, S. Vanni Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy Endothelin-1 system in the human failing heart Circ Res 86 2000 377 385
98. A. Wackenfors, M. Emilson, R. Ingemansson Ischemic heart disease induce upregulation of endothelin receptor mRNA in human coronary arteries Eur J Pharmacol 484 2004 103 109
99. D. Giannessi, S. Del Ry, R.L. Vitale The role of endothelins and their receptors in heart failure Pharmacol Res 43 2001 111 126
100. J.M. Tovar, J.G. Gums Tezosentan in the treatment of acute heart failure Ann Pharmacother 37 2003 1877 1883
101. G. Cotter, W. Kiowski, E. Kaluski Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure Eur J Heart Fail 3 2001 457 461
102. A. Louis, J.G. Cleland, S. Crabbe Clinical trials update CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER, and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology 2001 Eur J Heart Fail 3 2001 381 387
103. C.M. O'Connor, W.A. Gattis, K.F. Adams Jr Tezosentan in patients with acute heart failure and acute coronary syndromes results of the Randomized Intravenous TeZosentan Study (RITZ-4) J Am Coll Cardiol 41 2003 1452 1457
104. E. Kaluski, I. Kobrin, R. Zimlichman RITZ-5: Randomized Intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study J Am Coll Cardiol 41 2003 204 210
105. G.M. Keating, K.L. Goa Nesiritide A review of its use in acute decompensated heart failure Drugs 63 2003 47 70
106. I. Zineh, R.S. Schofield, J.A. Johnson The evolving role of nesiritide in advanced decompensated heart failure Pharmacotherapy 23 2003 1266 1280
107. H. Yasue, M. Yoshimura, H. Sumida Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure Circulation 90 1994 195 203
108. E.R. Levin, D.G. Gardner, W.K. Samson Natriuretic peptides N Engl J Med 339 1998 321 328
109. Publication Committee for the VMAC Investigators Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure A randomized controlled trial JAMA 287 2002 1531 1540
110. W.S. Colucci, U. Elkayam, D.P. Horton Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated heart congestive heart failure N Engl J Med 343 2000 246 253
111. M. Hirose, Y. Furukawa, F. Kurogouchi C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations J Pharmacol Exp Ther 286 1998 70 76
112. K.T. Jensen, J. Carstens, E.B. Pedersen Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans Am J Physiol 274 1998 F63 F72
113. W.T. Abraham, B.D. Lowes, D.A. Ferguson Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human natriuretic peptide in patients with hemodynamically decompensated heart failure J Card Fail 4 1998 37 44
114. C. Mueller, L. Scholer, K. Laule-Kilian Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea N Engl J Med 350 2004 647 650
115. V. Bhatia, P. Nayyar, S. Dhindsa Brain natriuretic peptide in diagnosis and treatment of heart failure J Postgrad Med 49 2003 182 185
116. J.A. deLemos, D.K. McGuire, M.H. Drazner B-type natriuretic peptide in cardiovascular disease Lancet 362 2003 316 322
117. A.J. Burger, D.P. Horton, T. LeJemel The effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated heart failure The PRECEDENT study Am Heart J 144 2002 1102 1108
118. W.F. Peacock 4th, C.L. Emerman, J. Young Nesiritide in congestive heart failure with acute coronary syndrome A pilot study of safety and efficacy J Card Fail 10 2004 120 125
119. R.M. Mills, R.E. Hobbs Nesiritide in perspective Evolving approaches to the management of acute decompensated heart failure Drugs Today 39 2003 767 774
120. G. Cotter, E. Kaluski, O. Milo LINCS L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock. A prospective randomized trial Eur Heart J 24 2003 1287 1295
121. J. Kunes, S. Honja, M. Kadlecova Altered balance of vasoactive systems in experimental hypertension The role of relative NO deficiency Physiol Res 53 suppl 1 2004 S23 S34
122. O. Pechanova, Z. Dobesova, J. Cejka Vasoactive systems in L-NAME hypertension The role of inducible nitric oxide synthase J Hypertens 22 2004 167 173
123. N. Lim, M.J. Dubois, D. De Backer Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest 124 2003 1885 1891
124. V. Menon Cardiogenic shock Have we really found the magic potion? Eur Heart J 24 2003 1279 1281